期刊文献+

玻璃体腔注射雷珠单抗联合视网膜激光光凝术治疗视网膜分支静脉阻塞继发黄斑水肿的效果观察 被引量:19

Treatment of macular edema secondary to retinal veinocclusion with introvirtreal ranibizumab combined with retinal photocoagulation
原文传递
导出
摘要 目的目的对视网膜分支静脉阻塞继发黄斑水肿采用玻璃体腔注射雷珠单抗联合视网膜激光光凝术治疗的有效性进行对比和观察。方法选择我院确诊的90例(90眼)符合入组标准的视网膜分支静脉阻塞继发性黄斑水肿的患者作为研究对象,按随机数字表分为Ⅰ组、Ⅱ组、Ⅲ组,每组各30例(30眼),Ⅰ组患者单纯予以玻璃体腔注射雷珠单抗0.05ml/0.5mg治疗,Ⅱ组患者单纯予以黄斑区格栅样光凝术治疗,Ⅲ组先予以玻璃体腔注射雷珠单抗治疗,1周后再予以视网膜激光光凝术治疗,治疗前、治疗后3、6个月采用Log MAR视力表检查最佳矫正视力(BCVA),采用光学相关断层扫描(OCT)检查黄斑中心凹厚度(CMT),评价临床疗效。结果Ⅰ组、Ⅱ组、Ⅲ组治疗后3、6个月的BCVA均较治疗前明显升高(均P<0.05),Ⅰ组、Ⅱ组、Ⅲ组治疗后3、6个月BCVA差异具有统计学意义(P<0.05),Ⅰ组、Ⅱ组治疗后3、6个月的BCVA升高值均明显小于Ⅲ组(P<0.05)。Ⅰ组、Ⅱ组、Ⅲ组治疗后3、6个月的CMT均较治疗前降低(均P<0.05),Ⅰ组、Ⅱ组、Ⅲ组治疗后3、6个月的CMT差异具有统计学意义(P<0.05),Ⅰ组、Ⅱ组治疗后3、6个月CMT降低值明显小于Ⅲ组(P<0.05)。Ⅲ组治疗3、6个月的临床疗效效果高于Ⅰ组、Ⅱ组(P<0.05)。结论玻璃体腔注射雷珠单抗联合视网膜激光光凝术治疗视网膜分支静脉阻塞继发黄斑水肿的效果优于单纯注药或者单纯光凝的效果,对视力改善及促进黄斑水肿吸收的效果更快、更好。 Objective To investigate the clinical effect of introvitrealranibizumab combined with retinal photocoagulation for the treatment of macular edema secondary to retinal vein occlusion. Methods Ninety eyes (90 patients) diagnosed with retinal vein occlusion in our hospital were included into this study, and were randomly assigned into 3 groups. GroupIreceived intravitreal ranibizumab 0.05ml/0.5mg;group IIwere treated with macular grid photocoagnlation; and group Ⅲ were treated with intra-vitrealranibizumab0.05ml/0.5mg combined with macular grid photocoagulation 1 week later. Best corrected visual acuity (BCVA) were measured using LogMAR, 3 months and 6 months postoperatively, central macular thickness (CMT) were recorded using optical coherence tomography(OCT). Results All groups had better BCVA 3 months and 6 months postoperatively than preoperative. BCVA and the differences were statistically significant (P〈0.05); BCVA improvement of groupⅢwas significant than that of group Ⅰ and group Ⅱ(P〈0.05).All groups have decreased CMT 3 months and 6 months postoperatively than preoperative CMT and the differences were statistically significant (P〈0.05); CMT improvement of group Ⅲwas better than that of groupⅠ and group Ⅱ (P〈0.05); group Ⅲhad better clinical effect than that of group Ⅱ and group Ⅰ. Conclusion Better clinical effect such as BCVA and CMT improvement with the treatment of macular edema secondary to retinal vein occlusion can be obtained using introvitreal ranibizumab combined with retinal photocoagulation when compared with introvitreal ranibizumab or retinal photocoagulation alone.
作者 韩崧 刘敬花
出处 《北京医学》 CAS 2017年第4期347-350,共4页 Beijing Medical Journal
关键词 视网膜分支静脉阻塞 黄斑水肿 激光光凝 雷珠单抗 联合治疗 branch retinal vein occlusion macular edema retinal photocoagulation ranibizumab combined treatment
  • 相关文献

参考文献5

二级参考文献68

  • 1Avinoam Ophir,Rana Hanna,Michael R.Martinez.Importance of 3-D image reconstruction of spectraldomain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema[J].International Journal of Ophthalmology(English edition),2013,6(6):836-843. 被引量:1
  • 2Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovaseular age-related maeular degeneration. N Engl J Med, 2006,355 : 1432-1444.
  • 3Boyer DS, Heier JS, Brown DM, et al. A phase Ⅲ b study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology, 2009, 116: 1731-1739.
  • 4Rosenfeld PJ, Brown DM, Heier .IS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006,355 : t419-1431.
  • 5Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and hevacizumab for treatment of neovascular age-related macular degeneration : two-year results. Ophthalmology, 2012,119 : 1388-1398.
  • 6Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf,2010,9 : 149-165.
  • 7Regillo cD, Brown DM. Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovaseular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol, 2008,145 : 239-248.
  • 8Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology, 2012,119 : 1175-1183.
  • 9Meyer CH, Eter N, Holz FG, SUSTAIN Study Group. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration: interim results from the SUSTAIN trial[J/OL]. Invest Ophthalmol Vis Sei, 2008,49: E-Abstract 273 [2012-10- 01]. http://abstracts, iovs. org//egi/content/abstract/49/5/ 2737 sid=f535047f-Ofa5-485e-97ff-2d18d2f73flf.
  • 10Holz FG, Meyer C, Eter N. Safety and efficacy of ranibizumab treatment in patients with neovaseular age-related maeular degeneration: 12-month results of the SUSTAIN study[J/OL]. Invest Ophthalmol Vis Sci, 2009,50 : E-Abstract 3095 [2012-10- 01]. http://abstracts, iovs. org//cgi/content/abstract/50/5/ 3095? sid= ccf36cd8-060e-4a80-ga01-c387f330f34d.

共引文献55

同被引文献157

引证文献19

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部